---
layout: default
title: Ammonium Chloride
parent: 僅模型預測 (L5)
nav_order: 332
evidence_level: L5
indication_count: 2
---

# Ammonium Chloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ammonium Chloride: From Expectorant Use to Acute Laryngopharyngitis

## One-Sentence Summary

Ammonium Chloride is a traditional expectorant agent with a long history of use in respiratory symptom relief, primarily acting to thin and mobilize respiratory secretions.
The TxGNN model predicts it may be effective for **Acute Laryngopharyngitis**,
however with **0 clinical trials** and **0 publications** currently supporting this specific direction, evidence remains at the model-prediction level only.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Expectorant (respiratory secretion facilitation) |
| Predicted New Indication | Acute Laryngopharyngitis |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| US Market Status | Not marketed in Taiwan (no regulatory records found) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from DrugBank for this compound. Based on established pharmacological knowledge, Ammonium Chloride is a classical expectorant that works by stimulating the gastric-pulmonary vagal reflex, promoting secretion from bronchial and upper airway mucosal glands, thereby reducing mucus viscosity and facilitating clearance.

Acute laryngopharyngitis is characterized by inflammation of the laryngeal and pharyngeal mucosa, accompanied by mucus accumulation and irritative cough. The pro-secretory and mucolytic mechanism of Ammonium Chloride is theoretically relevant to this pathology — by reducing mucosal dryness and thinning accumulated secretions, it could plausibly alleviate the foreign-body sensation and irritation characteristic of acute laryngopharyngitis.

However, this mechanistic link is based entirely on pharmacological analogy. The TxGNN high score (0.9994) most likely originates from co-occurrence relationships between Ammonium Chloride and upper respiratory disease nodes in the knowledge graph, rather than from direct clinical evidence. No clinical trials or peer-reviewed literature specifically addressing this indication were identified during the evidence search.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

Ammonium Chloride has no regulatory approval records in the Taiwan FDA database. No NDA or license information is available for tabulation.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model assigns a high prediction score (99.94%), suggesting a plausible mechanistic connection between Ammonium Chloride's expectorant properties and acute laryngopharyngitis; however, the complete absence of clinical trials, published literature, and regulatory approval records means this candidate rests entirely on model inference with no empirical clinical validation. Advancing without foundational safety and efficacy data would not be appropriate.

**To proceed, the following is needed:**
- Full mechanism of action (MOA) documentation from DrugBank or primary literature
- Package insert warnings and contraindication data (currently unavailable — the TFDA label PDF should be retrieved and parsed to fill this critical gap)
- At minimum one exploratory clinical study or well-designed observational study demonstrating efficacy signals in acute laryngopharyngitis or a closely related upper airway inflammatory condition
- A clear disease subtype definition for any proposed trial — acute laryngopharyngitis must be distinguished from allergic, viral, and bacterial subtypes to enable a coherent study population
- Assessment of appropriate dosage form and route of administration for upper airway delivery
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

